In this video interview, David Morton, PhD, director of biostatistics at Certara, discusses how growing FDA support is accelerating the adoption of Bayesian approaches, enabling more flexible, ...

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...

The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.

In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease ...